Oligonucleotide based-strategies for allergy with special reference to siRNA.
BACKGROUND
Allergic diseases are a significant global health care problem. Current pharmacological approaches address symptoms but do not alter the underlying immune dysregulation. Current allergen-specific immunotherapy has several drawbacks. Therefore, approaches that attenuate allergic responses safely and effectively at the level of upstream causative events are desirable. Oligonuleotide-based therapies [CpG DNA, antisense oligonucleotides, and small interfering RNA (siRNA)] are promising approaches.


OBJECTIVE
We review developments in oligonucleotide-based therapies and the potential of siRNA for treating allergy.


CONCLUSIONS
Strategies with oligonucleotides basically aim to reduce T helper type 2 (Th2) responses. It is controversial whether the reduction of Th2 responses does, in fact, attenuate allergic diseases. Increased understanding of allergic mechanisms will enhance the efficacy of oligonucleotide-based therapy.
Suzuki
Motohiko
M
University of Western Ontario, University Hospital C9 - 136, Department of Surgery, London, Ontario, N6A 5A5, Canada.
Zheng
Xiufen
X
Zhang
Xusheng
X
Ichim
Thomas E
TE
Beduhn
Marianne E
ME
Min
Weiping
W